Related Experiment Video

Updated: Aug 22, 2026

Functional Characterization of Endogenously Expressed Human RYR1 Variants
07:59

Functional Characterization of Endogenously Expressed Human RYR1 Variants

Published on: June 9, 2021

Calstabin deficiency, ryanodine receptors, and sudden cardiac death

Stephan E Lehnart1, Xander H T Wehrens, Andrew R Marks

  • 1Department of Physiology and Cellular Biophysics, Center for Molecular Cardiology, Columbia University College of Physicians and Surgeons, 630W 168th Street, P&S 9-401, New York, NY 10032, USA. sel2004@columbia.edu

Biochemical and Biophysical Research Communications
|September 1, 2004
PubMed

Insights

Calstabin2 dissociation from cardiac ryanodine receptors (RyR2) causes calcium leaks in heart failure and arrhythmias. Restoring calstabin2 binding is key for normal heart function and preventing sudden cardiac death.

Area of Science:

  • Cardiovascular Physiology
  • Molecular Cardiology
  • Biochemistry

Background:

  • Cardiac ryanodine receptor 2 (RyR2) controls intracellular calcium release from the sarcoplasmic reticulum.
  • Calstabin2 (FKBP12.6) is a critical regulatory protein that binds to RyR2.
  • Dysfunctional RyR2 is implicated in heart failure and arrhythmias.

Purpose of the Study:

  • To review the role of calstabin2 in RyR2 function and cardiac excitation-contraction coupling.
  • To discuss how calstabin2 dysregulation contributes to heart failure and arrhythmias.

Main Methods:

  • Literature review of studies on RyR2, calstabin2, and cardiac function.
  • Analysis of PKA phosphorylation effects on calstabin2-RyR2 interaction.
  • Examination of genetic mutations affecting calstabin2 binding.

Main Results:

  • PKA hyper-phosphorylation of RyR2 in heart failure reduces calstabin2 binding, causing diastolic calcium leak.
  • Genetic mutations associated with arrhythmias also decrease calstabin2 affinity for RyR2.
  • Calstabin2 dissociation leads to impaired calcium cycling and reduced cardiac contractility.

Conclusions:

  • Calstabin2 binding is essential for normal RyR2 channel function and cardiac contractility.
  • Dysregulation of calstabin2 binding to RyR2 is a central mechanism in heart failure and triggered arrhythmias.
  • Targeting calstabin2 interactions may offer therapeutic strategies for cardiovascular diseases.

More Related Videos

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia09:36

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

A Protocol for Immunohistochemistry and RNA In-situ Distribution within Early Drosophila Embryo14:34

A Protocol for Immunohistochemistry and RNA In-situ Distribution within Early Drosophila Embryo

Published on: May 6, 2022

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...